About this Research Topic
The development of tumor immunotherapy provides a huge breakthrough in the prognosis and treatment of tumors. For example, cancer vaccines, oncolytic virotherapy, adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs) all provide different solutions for tumor immunotherapy. Especially ICIs have achieved great success in clinical applications. We can even use immune scoring to quantify the infiltration degree of T cells that play a central role in immunotherapy to evaluate and predict the therapeutic effect of PD-1/PD-L1 and CTLA4. These achievements in tumor treatment and prognosis are encouraging, but the restricted response rates of tumor immunotherapy, unpredictable clinical efficacy, and potential side effects including autoimmune reactions or cytokine release syndrome still prevent the further application of immunotherapy in the clinic. There are many possible reasons for this, such as defects in antigen presentation mechanisms, immunosuppressive cell aggregation and immune evasion, which further affect the treatment and prognosis of patients. In order to address the above dilemma encountered in tumor immunotherapy, we need to further investigate the molecular mechanisms of immune-related diagnostic and prognostic markers or new molecular therapeutic targets for cancer patients to achieve accurate and more effective immunotherapy. In conclusion, the development of tumor immunology brings us great opportunities as well as a series of challenges.
In this Research Topic, we aim to explore molecular mechanisms underlying immune-related diagnostic and prognostic biomarkers of cancer as well as novel molecular therapeutic targets. Using these biomarkers and molecular targets, we can improve the clinical benefit of patients by performing precision therapy for patients sensitive to targeted therapy or immunotherapy.
We welcome Original Research, Reviews, and Systematic Reviews including but not limited to the following themes:
1. Knowledge-based development of novel immune-related therapeutic agents, targeted therapeutics and treatment options for cancer
2. Mechanisms underlying the functions of biomarkers in the diagnosis, immunotherapy and prognostic value of cancer patients
3. Immune-related molecular mechanisms involved in tumor initiation and progression
4. Novel methods for immune-related biomarker detection using tissue, blood or urine
5. Discovery of novel immune checkpoint molecules in cancer
● Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases without accompanying validation are outside the scope of this section and will not be accepted as part of this Research Topic.
In this Research Topic, we aim to explore molecular mechanisms underlying immune-related diagnostic and prognostic biomarkers of cancer as well as novel molecular therapeutic targets. Using these biomarkers and molecular targets, we can improve the clinical benefit of patients by performing precision therapy for patients sensitive to targeted therapy or immunotherapy.
We welcome Original Research, Reviews, and Systematic Reviews including but not limited to the following themes:
1. Knowledge-based development of novel immune-related therapeutic agents, targeted therapeutics and treatment options for cancer
2. Mechanisms underlying the functions of biomarkers in the diagnosis, immunotherapy and prognostic value of cancer patients
3. Immune-related molecular mechanisms involved in tumor initiation and progression
4. Novel methods for immune-related biomarker detection using tissue, blood or urine
5. Discovery of novel immune checkpoint molecules in cancer
● Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases without accompanying validation are outside the scope of this section and will not be accepted as part of this Research Topic.
Keywords: immune-related biomarkers, prognostic biomarkers, molecular therapeutic targets, immunotherapy, cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
